TU-2100
QX ID: 276
Generic Name:
n/a
Code name:
TU-2100
Indication:
Acne
Alopecia
Dermatitis
Psoriasis
Locations where ventures sought:
World
Stage of development:
Phase II
Preclinical
Type of venture sought:
Co-development
Joint venture
Brand Name:
Brand Name:
n/a
Mechanism: Please e-mail for further details.
Patent Info: Patents pending worldwide.
Description: TU-2100 is a topical medication for ACNE, PSORIASIS and
SEBORRHEIC DERMATITIS. It is a Dual Action Prodrug (DAPDRUG), i.e.,
conjugate of two biologically-active molecules, particularly
designed to penetrate the skin and exert a plurality of effects in
the skin.
The following properties characterize TU-2100:
SEBOSTATIC EFFECT: A clinical study revealed that TU-2100
effectively reduces sebum production and excretion.
ANTI-ACNE EFFECT: TU-2100 decreases the number of acne lesions and
lowers their intensity after 3-4 weeks of treatment, without any
skin irritation.
ANTI-SEBORRHEIC EFFECT: Human experience indicates that TU-2100
ameliorates the clinical signs of SEBORRHEIC DERMATITIS after 1 week
of topical treatment.
COMEDOLYTIC EFFECT: Studies in the rabbit ear model for acne showed
that TU-2100 exerts a strong comedolytic effect, similar to Retin A.
KERATINOCYTE INHIBITION: In vitro studies revealed that TU-2100
inhibits skin cell proliferation, without cytotoxicity.
TU-2100 IS NON-TOXIC: A series of toxicological studies did not
reveal any significant safety concerns.
According to a Phase II, randomized, double blind and placebo
controlled clinical trial, which involved 42 mild to moderate acne
patients, who were treated topically twice a day for 12 weeks, TU-
2100 is safe and effective for acne.
TU-2100’s effect was noted soon after commencement of treatment,
reaching statistically significant reduction in lesion count after
three weeks. Fifty nine percent reduction in total lesion count was
recorded after 12 weeks of treatment. (By comparison, Retin A, which
is the current "Gold Standard" in topical acne therapy, reduces
lesions 50-60% after 12 weeks, and no significant effect can be seen
after 3 weeks.) The Placebo reduced lesion number by 23%, with no
statistical significance comparing to baseline. TU-2100 was found to
be non irritant. No occurrence of skin irritation was noted in the
TU-2100 10% group, while in the placebo group there were few cases
of mild and transient skin reaction. (By comparison, Retin A and
causes moderate to severe irritation in more than 50% of the cases.)
TU-2100 is currently being tested in further Phase II clinical
studies in seborrheic dermatitis and psoriasis